Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 8/20 | 0.57 |
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.55 |
| ▸ | GCGR | P47871 | 1/20 | 0.55 |
| ▸ | GIPR | P48546 | 1/20 | 0.55 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.53 |
| ▸ | CCKBR | P32239 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199030 | 0.89 | CXCL8 (0.57) | IL23RKISS1RCCKBR | |
| SCHEMBL29850431 | 0.84 | GLP1R (0.64) | KISS1RRXFP1GLP1RPTH1R | |
| SCHEMBL30721593 | 0.84 | MAGI3 (0.58) | IL23RKISS1REDNRARXFP1MAGI3 | |
| SCHEMBL29377904 | 0.84 | RXFP1 (0.57) | IL23REDNRARXFP1GLP1RGCGR | |
| SCHEMBL21305550 | 0.84 | RXFP1 (0.57) | IL23REDNRARXFP1GLP1RGCGR | |
| SCHEMBL31331962 | 0.83 | GLP1R (0.57) | GLP1RPTH1R | |
| SCHEMBL1651126 | 0.83 | GLP1R (0.70) | IL23RKISS1RGLP1RCCKBR | |
| SCHEMBL29406053 | 0.83 | GLP1R (0.70) | IL23RKISS1RGLP1RCCKBR | |
| SCHEMBL29393291 | 0.83 | GLP1R (0.69) | IL23RKISS1RRXFP1GLP1RGCGR | |
| SCHEMBL4592217 | 0.83 | IL23R (0.62) | IL23RRXFP1GLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10667935-B2 | Methods for making conjugates from disulfide-containing proteins | NOVARTIS AG (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190038444-A1 | METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-02-07 | — | — | US | disclosed |
| US-10172948-B2 | Methods for oxime conjugation to ketone-modified polypeptides | NOVARTIS AG (CH) | 2019-01-08 | — | — | US | disclosed |
| US-10022256-B2 | Methods for making conjugates from disulfide-containing proteins | NOVARTIS AG (CH) | 2018-07-17 | — | — | US | disclosed |
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038444-A1 | METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS | PDIA6, PTMS, PDIA3 | IL23R 3388/4885KISS1R 1080/4885EDNRA 4243/4885 |
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | PTMS, CRYAA, KRTCAP2 | IL23R 3529/4885KISS1R 725/4885EDNRA 3377/4885 |
| US-10667935-B2 | Methods for making conjugates from disulfide-containing proteins | PDIA6, PTMS, PDIA3 | IL23R 3388/4885KISS1R 1080/4885EDNRA 4243/4885 |
| US-10172948-B2 | Methods for oxime conjugation to ketone-modified polypeptides | PTMS, CRYAA, KRTCAP2 | IL23R 3529/4885KISS1R 725/4885EDNRA 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.